39949395|t|Effects of dexmedetomidine-ropivacaine assisted combined spinal-epidural anesthesia on neutrophil-lymphocyte ratio and postoperative delirium in elderly patients with intertrochanteric femoral fracture.
39949395|a|Objective: Intertrochanteric femoral fracture (IFF) is a public issue in the old. Combined spinal-epidural anesthesia (CSEA) is commonly utilized for lower limb orthopedic surgery in elderly patients. Therefore, this study explored the application of dexmedetomidine (Dex) and ropivacaine (Rop) assisted CSEA in elderly IFF patients. Methods: Totally 187 elderly IFF patients were assigned into the Rop assisted CSEA (Rop-CSEA), low-dose Dex-Rop assisted CSEA (low Dex and Rop-CSEA) and high-dose Dex-Rop assisted CSEA (high Dex and Rop-CSEA) groups. We compared block effects, hemodynamic indicators [heart rate (HR)/respiratory rate (RR)/mean arterial pressure (MAP)] at time before anesthesia (T0)/skin incision (T1)/10 min postoperatively (T2)/suture postoperatively (T3)/anesthesia recovery (T4), postoperative pain mediator release [substance P (SP)/prostaglandin E2 (PGE2)/5-hydroxytryptamine (5-HT)], neutrophil-lymphocyte ratio (NLR), adverse reactions, delirium and cognitive dysfunction incidence. Results: Compared with the Rop-CSEA group, low/high Dex and Rop-CSEA groups had shortened onset times, prolonged recovery times in sensory/motor block, elevated HR/RR/MAP, repressed pain mediator release, and reduced postoperative delirium and cognitive dysfunction incidences. HR/RR/MAP exhibited reductions followed by elevations at T2-T4, and SP/PGE2/5-HT levels revealed elevations in all groups postoperatively. NLR level displayed enhancement followed by reduction, and NLR in the low/high Dex and Rop-CSEA groups was abated on postoperative days 1-5. Total incidence of adverse reactions in the high Dex and Rop-CSEA group was enhanced. Conclusion: Dex and Rop assisted CSEA shortens the onset time of anesthesia, maintains perioperative hemodynamic stability, inhibits pain mediator release, reduces postoperative NLR level and the incidence of delirium and cognitive dysfunction in IFF patients.
39949395	11	26	dexmedetomidine	Chemical	MESH:D020927
39949395	27	38	ropivacaine	Chemical	MESH:D000077212
39949395	119	141	postoperative delirium	Disease	MESH:D000071257
39949395	153	161	patients	Species	9606
39949395	167	201	intertrochanteric femoral fracture	Disease	MESH:D006620
39949395	214	248	Intertrochanteric femoral fracture	Disease	MESH:D006620
39949395	250	253	IFF	Disease	MESH:D006620
39949395	394	402	patients	Species	9606
39949395	454	469	dexmedetomidine	Chemical	MESH:D020927
39949395	471	474	Dex	Chemical	MESH:D020927
39949395	480	491	ropivacaine	Chemical	MESH:D000077212
39949395	493	496	Rop	Chemical	MESH:D000077212
39949395	523	526	IFF	Disease	MESH:D006620
39949395	527	535	patients	Species	9606
39949395	566	569	IFF	Disease	MESH:D006620
39949395	570	578	patients	Species	9606
39949395	602	605	Rop	Chemical	MESH:D000077212
39949395	621	624	Rop	Chemical	MESH:D000077212
39949395	641	644	Dex	Chemical	MESH:D020927
39949395	645	648	Rop	Chemical	MESH:D000077212
39949395	668	671	Dex	Chemical	MESH:D020927
39949395	676	679	Rop	Chemical	MESH:D000077212
39949395	700	703	Dex	Chemical	MESH:D020927
39949395	704	707	Rop	Chemical	MESH:D000077212
39949395	728	731	Dex	Chemical	MESH:D020927
39949395	736	739	Rop	Chemical	MESH:D000077212
39949395	1005	1023	postoperative pain	Disease	MESH:D010149
39949395	1042	1053	substance P	Gene	6863
39949395	1059	1075	prostaglandin E2	Chemical	MESH:D015232
39949395	1077	1081	PGE2	Chemical	MESH:D015232
39949395	1083	1102	5-hydroxytryptamine	Chemical	MESH:D012701
39949395	1104	1108	5-HT	Chemical	MESH:D012701
39949395	1166	1174	delirium	Disease	MESH:D003693
39949395	1179	1200	cognitive dysfunction	Disease	MESH:D003072
39949395	1239	1242	Rop	Chemical	MESH:D000077212
39949395	1264	1267	Dex	Chemical	MESH:D020927
39949395	1272	1275	Rop	Chemical	MESH:D000077212
39949395	1394	1398	pain	Disease	MESH:D010146
39949395	1429	1451	postoperative delirium	Disease	MESH:D000071257
39949395	1456	1477	cognitive dysfunction	Disease	MESH:D003072
39949395	1558	1560	SP	Gene	6863
39949395	1561	1565	PGE2	Chemical	MESH:D015232
39949395	1566	1570	5-HT	Chemical	MESH:D012701
39949395	1708	1711	Dex	Chemical	MESH:D020927
39949395	1716	1719	Rop	Chemical	MESH:D000077212
39949395	1819	1822	Dex	Chemical	MESH:D020927
39949395	1827	1830	Rop	Chemical	MESH:D000077212
39949395	1868	1871	Dex	Chemical	MESH:D020927
39949395	1876	1879	Rop	Chemical	MESH:D000077212
39949395	1989	1993	pain	Disease	MESH:D010146
39949395	2065	2073	delirium	Disease	MESH:D003693
39949395	2078	2099	cognitive dysfunction	Disease	MESH:D003072
39949395	2103	2106	IFF	Disease	MESH:D006620
39949395	2107	2115	patients	Species	9606
39949395	Negative_Correlation	MESH:D020927	MESH:D003072
39949395	Negative_Correlation	MESH:D020927	MESH:D000071257
39949395	Cotreatment	MESH:D000077212	MESH:D020927
39949395	Negative_Correlation	MESH:D000077212	MESH:D006620
39949395	Association	MESH:D012701	MESH:D010149
39949395	Negative_Correlation	MESH:D020927	MESH:D010146
39949395	Negative_Correlation	MESH:D000077212	MESH:D003072
39949395	Negative_Correlation	MESH:D000077212	MESH:D000071257
39949395	Positive_Correlation	MESH:D015232	MESH:D020927
39949395	Negative_Correlation	MESH:D000077212	MESH:D010146
39949395	Positive_Correlation	MESH:D012701	MESH:D020927
39949395	Association	MESH:D015232	MESH:D010149
39949395	Negative_Correlation	MESH:D020927	MESH:D006620
39949395	Positive_Correlation	MESH:D020927	6863
39949395	Positive_Correlation	MESH:D000077212	MESH:D015232
39949395	Positive_Correlation	MESH:D000077212	6863

